Results 51 to 60 of about 26,546,604 (292)

From junk to function — How weak selection in eukaryotes builds new parts and drives genomic complexity

FEBS Letters, EarlyView.
How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment with a cholinesterase inhibitor and memantine in Switzerland

Swiss Medical Weekly, 2012
QUESTIONS UNDER STUDY: The objective of this study was to estimate the potential budget impact and cost-effectiveness of the combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
Alena M. Pfeil, Reto W. Kressig, Thomas D. Szucs   +2 more
doaj   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Single-chamber pacemakers: with or without leads? Cost-effectiveness and cost-utility analyses

Annals of Medicine
Introduction The evolution in pacemaker technologies has led to improvements in size, weight, functionality, and durability, even as the battery and electrode-based structural configuration has remained essentially the same.Objective To compare the cost ...
José Ramón Lago-Quinteiro, Francisco Reyes-Santias, Manel Antelo, Vicent Caballer-Tarazona, José Luis Martinez-Sande, Javier Garcia-Seara, Moisés Rodriguez-Manero, Jose Ramon Gonzalez-Juanatey   +7 more
doaj   +1 more source

Cost-Utility Analysis of the Cochlear Implant in Children [PDF]

JAMA, 2000
Barriers to the use of cochlear implants in children with profound deafness include device costs, difficulty assessing benefit, and lack of data to compare the implant with other medical interventions.To determine the quality of life and cost consequences for deaf children who receive a cochlear implant.Cost-utility analysis using preintervention ...
A K, Cheng, H R, Rubin, N R, Powe, N K, Mellon, H W, Francis, J K, Niparko   +5 more
openaire   +2 more sources

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Cost-effectiveness plane: Cost-utility analysis with life-time horizon.

Cost-effectiveness plane: Cost-utility analysis with life-time horizon.
Dyfrig Hughes (40543), Bernd Duller (3834748), Elke Naujokat (18358266), Huw Lloyd Williams (18495674), Emily Holmes (418302), Christian P. Subbe (18495677)   +5 more
core   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Other title: Senate Bill 515 - Testimony on Behalf of the Citizens' Utility Ratepayer Board by David Springe, Consumer Counsel, Citizens' Utility Ratepayer Board

, 2008
application/pdf; "February 6, 2008."; Includes a copy of testimony on House Bill 2682 presented before the Kansas Legislature, House Utilities Committee, by David Springe, Consumer Counsel, Citizens' Utility Ratepayer Board on January 31, 2008.;
Springe, David.
core   +1 more source